Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-07-27Clinical Trial Update: 2 Arm Study of Clofarabine IV in MDS Patients [Phase 2]
Phase 2 trial evaluating intravenous Clofarabine in patients with myelodysplastic syndrome and leukemia has completed, with results posted i…
-
CLINICAL_TRIALS trial_result · 2012-07-26Clinical Trial Update: Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant [Phase 1]
Phase 1 safety study of interleukin-7 in recipients of a hematopoietic stem cell transplant (peripheral blood) has completed.
-
CLINICAL_TRIALS trial_result · 2012-06-12Clinical Trial Update: Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 trial update evaluating chemotherapy plus bone marrow transplantation with filgrastim in patients with acute myeloid leukemia or mye…
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A Phase 1/Phase 2 study of TLK199 tablets in patients with Myelodysplastic Syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2012-05-15Clinical Trial Update: Busulfan and Fludarabine in Patients With AML and MDS [Phase 2]
Phase 2 trial evaluating a busulfan and fludarabine regimen in patients with acute myeloid leukemia and myelodysplastic syndrome has complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-04-27Clinical Trial Update: Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 [Phase 2]
Phase 2 clinical trial update assessing lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with deletion 5q or mo…
-
CLINICAL_TRIALS trial_result · 2012-03-19Clinical Trial Update: AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS) [Phase 2]
Pfizer's axitinib (AG-013736) was studied in a Phase 2 trial in patients with poor-prognosis acute myeloid leukemia or myelodysplastic syndr…
-
CLINICAL_TRIALS trial_result · 2012-01-26Clinical Trial Update: Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation [Phase 2]
A Phase 2 clinical trial evaluating sirolimus plus tacrolimus for graft-versus-host disease prophylaxis after related stem cell transplantat…
-
CLINICAL_TRIALS trial_result · 2012-01-23Clinical Trial Update: Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation [Phase 2]
Phase 2 safety study evaluating the combination of azacitidine with donor lymphocyte infusion for relapsed acute myeloid leukemia or myelody…
-
CLINICAL_TRIALS trial_result · 2011-11-18Clinical Trial Update: Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
A multi-center trial update collecting survival data in subjects previously enrolled in Celgene protocol CC-5013-MDS-003 for myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2011-08-29Clinical Trial Update: ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS [Phase 2]
This is a Phase 2 clinical trial evaluating ClAraC or FLAMSA conditioning regimens followed by stem cell transplantation for high-risk acute…
-
CLINICAL_TRIALS trial_result · 2011-07-11Clinical Trial Update: Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) [Phase 3]
A Phase 3 trial evaluating 5-azacitidine (Vidaza) for treatment of imminent hematologic relapse in patients with acute myeloid leukemia or m…
-
CLINICAL_TRIALS trial_result · 2011-07-11Clinical Trial Update: Phase II 5-Azacytidine Plus VPA Plus ATRA [Phase 2]
Phase II clinical trial evaluating a combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in myelodysplastic syndrome an…
-
CLINICAL_TRIALS trial_result · 2011-06-22Clinical Trial Update: Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 pharmacokinetic study evaluating a 3-hour infusion of decitabine in adults with acute myeloid leukemia or myelodysplastic syndrome.
-
CLINICAL_TRIALS trial_result · 2011-05-26Clinical Trial Update: Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) [Phase 2]
This Phase 2 trial evaluated three dosing schedules of low-dose decitabine in patients with myelodysplastic syndrome and chronic myelomonocy…
-
CLINICAL_TRIALS trial_result · 2011-05-20Clinical Trial Update: Treatment of Myelodysplastic Syndromes Comparing Hydralazine/Ac. Valproic and Supportive Care in Patients Not Candidates, Refractory and/or Intolerant to Intensive Chemotherapy [Phase 2]
Phase 2 clinical trial evaluating the combination of hydralazine and valproic acid compared with supportive care in myelodysplastic syndrome…
-
CLINICAL_TRIALS trial_result · 2011-05-09Clinical Trial Update: Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). [Phase 2]
This Phase 2 trial compares clofarabine alone versus clofarabine with low-dose cytarabine in previously untreated acute myeloid leukemia and…
-
CLINICAL_TRIALS trial_result · 2011-04-14Clinical Trial Update: Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS [Phase 2]
Phase 2 trial evaluating cytokine-immunotherapy for low-risk myelodysplastic syndrome has completed. Results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-02-14Clinical Trial Update: Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A completed Phase I/II trial evaluating the combination of 5-azacytidine with cytarabine in patients with relapsed/refractory acute myeloid …
-
CLINICAL_TRIALS trial_result · 2011-02-14Clinical Trial Update: Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen [Phase 3]
This update reports the completion of a Phase 3 trial comparing Busulfan plus Cyclophosphamide versus Fludarabine as conditioning regimens f…
-
CLINICAL_TRIALS trial_result · 2010-10-22Clinical Trial Update: Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) [Phase 1, Phase 2]
This trial update reports on the safety and anti-disease activity of CHR-2797 (tosedostat) in elderly and/or treatment-refractory patients w…
-
CLINICAL_TRIALS trial_result · 2010-04-27Clinical Trial Update: Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 study of tipifarnib in high-risk myelodysplastic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2010-03-10Clinical Trial Update: 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1]
Completed Phase 1 study evaluating safety and initial efficacy of the combination of 3-AP followed by fludarabine in patients with relapsed …
-
CLINICAL_TRIALS trial_result · 2010-02-04Clinical Trial Update: Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 trial evaluating treosulfan-based conditioning for myelodysplastic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2009-11-16Clinical Trial Update: Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
This update reports on a completed trial comparing piperacillin-tazobactam alone versus with a glycopeptide in neutropenic patients with hem…